Bonmin

Aluminum Hydroxide: Vitamin D Analogs may increase the serum concentration of Aluminum Hydroxide. Specifically

the absorption of aluminum may be increased

leading to increased serum aluminum concentrations. Avoid combination Bile Acid Sequestrants: May decrease the serum concentration of Vitamin D Analogs. More specifically

bile acid sequestrants may impair absorption of Vitamin D Analogs. Management: Avoid concomitant administration of vitamin D analogs and bile acid sequestrants (eg

cholestyramine). Separate administration of these agents by several hours to minimize the potential risk of interaction. Monitor plasma calcium concentrations. Consider therapy modification Calcium Salts: May enhance the adverse/toxic effect of Vitamin D Analogs. Monitor therapy Cardiac Glycosides: Vitamin D Analogs may enhance the arrhythmogenic effect of Cardiac Glycosides. Monitor therapy Danazol: May enhance the hypercalcemic effect of Vitamin D Analogs. Monitor therapy Erdafitinib: Serum Phosphate Level-Altering Agents may diminish the therapeutic effect of Erdafitinib. Management: Avoid coadministration of serum phosphate level-altering agents with erdafitinib before initial dose increase period based on serum phosphate levels (Days 14 to 21). Consider therapy modification Mineral Oil: May decrease the serum concentration of Vitamin D Analogs. More specifically

mineral oil may interfere with the absorption of Vitamin D Analogs. Management: Avoid concomitant

oral administration of mineral oil and vitamin D analogs. Consider separating the administration of these agents by several hours to minimize the risk of interaction. Monitor plasma calcium concentrations. Consider therapy modification Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Vitamin D Analogs. Avoid combination Multivitamins/Minerals (with ADEK

Folate